Antibiotice reports Q2 2026 revenue decline exceeding projections

Antibiotice (ATB) reported a 10.37% year-on-year decrease in net turnover for Q2 2026, underperforming its internal target of a 7.34% decline. The company also recorded an operating margin of 10%, signaling potential operational headwinds for the state-owned pharmaceutical entity.